Neumología

Asma Severa

Biologic therapy (omalizumab, mepolizumab, dupilumab) and bronchial thermoplasty for severe asthma.

Opciones de Tratamiento

Centros Recomendados

$6,000

Desde

7-21 días

Espera Típica

Planes de Tratamiento para Asma Severa

Compare opciones basadas en evidencia en los principales hospitales chinos — precios transparentes, tiempos de espera y recuperación.

Plan Principal

Mepolizumab Therapy (12 months)

Anti-IL-5 monthly injection for eosinophilic severe asthma.

Tiempo de Espera

5-7 days

Estancia Hospitalaria

12 monthly doses

Recuperación

Outpatient

Precio Estimado

Approx. $8,500/year

Ver Introducción Detallada — Procedimiento, Comparación de Precios y Más

Comparación de Precios: China vs EE.UU.

🇨🇳 China

$6,000

🇺🇸 EE.UU.

$30,000+

Ahorre hasta $24,000 por tratamiento

Pasos del Procedimiento

Pre-treatment: blood eosinophil count + IgE + FeNO + spirometry

Rule out other eosinophilic conditions (EGPA, parasitic)

Initial injection at infusion center: mepolizumab 100mg SC

Monthly SC injections at home after training (or clinic)

Every 3 months: asthma control assessment (ACT/ACQ)

Biomarker monitoring: eos count should decrease 80%+

Assess response at 4 months — continue if improvement

Step-down OCS and ICS doses based on control

What is Mepolizumab?

An anti-IL-5 monoclonal antibody that dramatically reduces exacerbations in severe eosinophilic asthma, COPD with eosinophilia, EGPA (Churg-Strauss), and hypereosinophilic syndrome. It targets the master regulator of eosinophil production.

Why China?

Cost (annual): $6,000-$12,000 vs. $30,000-$45,000 in the US
Biologics available: Mepolizumab, benralizumab, omalizumab all NMPA-approved
Severe asthma centers: West China, Zhongshan, PUMC — specialized units
Combination approach: Optimize inhaler technique + comorbidity management before escalating

Who is a candidate?

Severe eosinophilic asthma (≥150 eos/μL, recurrent exacerbations despite high-dose ICS/LABA)
Prednisone-dependent asthma
EGPA (Churg-Strauss)
Hypereosinophilic syndrome

Outcomes

Exacerbation reduction: 50-60%. Oral steroid reduction: 50-75%. Asthma control score improvement: clinically significant in 60-70%. Maintenance of response: durable with continued therapy.

Reservar Consulta Gratuita WhatsApp

Los precios son rangos indicativos en USD basados en tarifas publicadas. La cotización final depende de sus registros médicos y hospital seleccionado — solicite una estimación personalizada gratuita.